INS and Parkinson disease: Patients with PD primarily exhibit a significant loss of insulin receptor mRNA in the substantia nigra pars compacta, increased insulin IR, and reduced activation of molecules such as insulin receptor substrate 1 (IRS1) and protein kinase B (Akt) within the insulin metabolic pathway (24).